Samsung Biologics has updated the expected completion date for its $1.5 billion fifth plant. But in this op-ed, we ask whether this BIO-timed announcement is demonstrative of engineering expertise, shoddy forecasting, or a rabid media campaign? While industry has flocked to BIO this week, a family bereavement has meant this dejected journalist remains at home across the pond, sifting through the hundreds of prewritten press announcements trickling out of the Boston Convention and Exhibition Center (BCEC). One such release being…

CDMO WuXi Biologics will double bioreactor capacity at a facility in Wuppertal and add a second filling line at a plant in Leverkusen due to increased European demand. China-headquartered WuXi Biologics bolstered its presence in Europe in 2020, adding first a drug product plant in Leverkusen, Germany and then a drug substance plant in nearby Wuppertal. Three years on and the contract development and manufacturing organization (CDMO) has pledged an undisclosed amount to expand both sites to support “global clients’…